<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Hepatic lipase (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) is involved in the metabolism of several <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> and may contribute to the atherogenic <z:chebi fb="23" ids="18059">lipid</z:chebi> profile in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Little is known about the effect of cholesterol synthesis inhibitors on <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity in relation to sex and the hepatic lipase gene, the LIPC promoter variant in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we studied the effect of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg (A10) and 80 mg (A80) on <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity in 198 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: Patients (aged 45-75 years, without manifest <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, total cholesterol 4.0-8.0 mmol/l, and fasting <z:chebi fb="4" ids="17855">triglycerides</z:chebi> [TG] 1.5-6.0 mmol/l) were included in a double-blind, randomized, placebo-controlled trial for 30 weeks (<z:mp ids='MP_0002055'>Diabetes</z:mp> <z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> <z:chebi fb="23" ids="18059">Lipid</z:chebi> Intervention study) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity at baseline was significantly higher in our population compared with an age-matched control group without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (406 +/- 150 vs. 357 +/- 118 units/l) </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity in men versus women (443 +/- 158 vs. 358 +/- 127 units/l), in carriers of the LIPC C/C allele versus carriers of the T/T allele (444 +/- 142 vs. 227 +/- 96 units/l), and in Caucasians versus blacks (415 +/- 150 vs. 260 +/- 127 units/l) <z:hpo ids='HP_0000001'>all</z:hpo> differed significantly (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> dose-dependently decreased <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> (A10, -11%; A80, -22%; both P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Neither sex nor the LIPC C--&gt;T variation influenced the effect of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> on <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Sex, LIPC promoter variant, and ethnicity significantly contribute to the baseline variance in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> treatment in diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> results in a significant dose-dependent decrease in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity, regardless of sex or the LIPC promoter variant </plain></SENT>
</text></document>